MOTION SICKNESS RELIEF- dimenhydrinate tablet L.N.K. International, Inc.

Quality Plus 44-198

Active ingredient (in each tablet)

Dimenhydrinate 50 mg

Purpose

Antiemetic

Uses

for prevention and treatment of these symptoms associated with motion sickness:

- nausea
- vomiting
- dizziness

Warnings

Do not use

for children under 2 years of age unless directed by a doctor.

Ask a doctor before use if you have

- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- difficulty in urination due to enlargement of the prostate gland

Ask a doctor or pharmacist before use if you are

taking sedatives or tranquilizers.

When using this product

- marked drowsiness may occur
- avoid alcoholic beverages
- alcohol, sedatives, and tranquilizers may increase drowsiness
- use caution when driving a motor vehicle or operating machinery

If pregnant or breast-feeding,

ask a health professional before use.

Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center (1-800-222-

Directions

 to prevent motion sickness, the first dose should be taken one-half to one hour before starting activity

Marc and	1 to 2 tablets every 4-6 hours; do not exceed 8 tablets in 24 hours, or as directed by a doctor
	$\frac{1}{2}$ to 1 tablet every 6-8 hours; do not exceed 3 tablets in 24 hours, or as directed by a doctor
children 2 to	$\frac{1}{2}$ tablet every 6-8 hours; do not exceed $1\frac{1}{2}$ tablets in 24 hours, or as directed by a doctor

Other information

- each tablet contains: calcium 35 mg
- see end flap for expiration date and lot number
- TAMPER EVIDENT: DO NOT USE IF OUTER PACKAGE IS OPENED OR BLISTER IS TORN OR BROKEN
- store at 25°C (77°F); excursions permitted between 15°-30°C (59°-86°F)
- protect from moisture

Inactive ingredients

croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid

Questions or comments?

1-800-426-9391

Principal display panel

QUALITY +PLUS

NDC 50844-199-02

*Compare to active ingredient in Dramamine® Original Formula

ORIGINAL FORMULA Motion Sickness Relief

Dimenhydrinate 50 mg • Antiemetic

PREVENTS NAUSEA, VOMITING & DIZZINESS FOR CHILDREN & ADULTS

12 Tablets

ACTUAL SIZE

*This product is not manufactured or distributed by Medtech Products Inc., owner of the registered trademark Dramamine® Original Formula.

TAMPER EVIDENT: DO NOT USE IF PACKAGE IS OPENED OR IF BLISTER UNIT IS TORN, BROKEN OR SHOWS ANY SIGNS OF TAMPERING

50844 REV0518A19802

Distributed by **LNK INTERNATIONAL, INC.** 60 Arkay Drive Hauppauge, NY 11788 USA



MOTION SICKNESS RELIEF

dimenhydrinate tablet **Product Information** NDC:50844-199 **Product Type** HUMAN OTC DRUG Item Code (Source) **Route of Administration ORAL Active Ingredient/Active Moiety Basis of Ingredient Name** Strength Strength

DIMENHYDRINATE 50 mg

Inactive Ingredients			
Ingredient Name	Strength		
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)			
DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)			
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			

Product Characteristics			
Color	white	Score	2 pieces
Shape	ROUND	Size	9mm
Flavor		Imprint Code	44;198
Contains			

I	Packaging					
4	tem Code	Package Description	Marketing Start Date	Marketing End Date		
1	NDC:50844-199- 02	2 in 1 CARTON	12/01/1992			
1		6 in 1 BLISTER PACK; Type 0: Not a Combination Product				

Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
OTC Monograph Drug	M009	12/01/1992		

Labeler - L.N.K. International, Inc. (038154464)

STEARIC ACID (UNII: 4ELV7Z65AP)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		038154464	pack(50844-199)

Establishment			
Name	Address	ID/FEI	Business Operations
LNK International, Inc.		832867837	manufacture(50844-199), pack(50844-199)

Establishment			
Name	Address	ID/FEI	Business Operations

LNK International, Inc. 117025878 manufacture(50844-199)

Revised: 2/2024 L.N.K. International, Inc.